Can't Get Retatrutide? What to Use Now Instead

By Kaden, founder of Weight Loss Provider Guide, an independent comparison resource for GLP-1 telehealth providers

Last verified: August 21, 2026 — U.S. pricing and access

Some links below are affiliate links. They don't change what we verify or what we recommend, and we point you to the cheaper non-affiliate route wherever one exists.

Can't get retatrutide? The closest FDA-approved alternative by receptor overlap is Zepbound, and it starts at $299 per 28-day supply. If needles are the dealbreaker, the Wegovy pill and Foundayo both start at $149 per 30-day supply.

Retatrutide is not approved in any country. The FDA says it cannot be used in compounding under federal law and that selling unapproved retatrutide for human use is illegal. Lilly plans to file with the FDA in the first quarter of 2027. A filing is not an approval.

Two things change your answer: whether your insurance covers GLP-1 medicines, and whether you already have a doctor who'll write a prescription.

But before you pick anything — there's a date you need to know about: August 31, 2026, ten days from this verification date. More on that in a second.

Four legal alternatives — plus the routes to actual retatrutide

Prices are self-pay medication prices verified August 21, 2026. Eligibility and program terms apply. Care, visit and lab costs may be separate.

→ Find my best legal path — answer a few questions about shots, pills, coverage and budget. You'll see your result on screen. No email required.

Why can't you get retatrutide right now?

Retatrutide is still an investigational drug — meaning it's being studied but hasn't been approved by any regulator anywhere in the world. Eli Lilly plans to submit its U.S. application in the first quarter of 2027, but a planned filing is not an approval. The FDA has also stated that retatrutide cannot be used in compounding under federal law.

Here's what changed this month, and why your source may have gone quiet.

August 12 is when the floor moved

Lilly filed six federal lawsuits against companies it says were selling retatrutide illegally. Five were filed in Texas and one in California. The defendants included online peptide sellers, a compounding pharmacy, and a med spa.

Alongside the lawsuits, Lilly said it had referred more than 200 people and businesses to the FDA, the Department of Justice, state attorneys general, law enforcement and licensing boards. It also flagged more than 14,000 websites, ads, posts and listings across 100+ countries.

Lilly's chief medical officer put it bluntly: what is being sold on the black market is "not worth the risk."

The part that may have shut your seller down

Buried in the same announcement was the piece that matters more than the lawsuits. Lilly publicly asked credit card companies, payment processors and shipping carriers to stop serving these sellers.

That's a real pressure point. A seller can keep a page online and still be unable to take cards or ship a package.

If your seller's checkout stopped working, went crypto-only, or the site simply disappeared, losing a payment or shipping service is one possible reason. We cannot know why any one seller vanished.

Why "compounded retatrutide" was never a legal workaround

Compounding is when a licensed pharmacy mixes a custom version of a medicine. It's legal for a lot of drugs. Not this one.

The FDA's words are short and there's no wiggle room in them: "Retatrutide and cagrilintide cannot be used in compounding under federal law." The agency adds that retatrutide isn't a component of any FDA-approved drug and hasn't been found safe and effective for any condition.

The FDA has also warned telehealth companies for marketing it, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it.

So a pharmacy offering "compounded retatrutide" isn't operating in a gray area. It's outside the law.

What the numbers say about what people were actually injecting

This is the part almost nobody publishes, and it's the strongest evidence we found.

U.S. poison centers logged an average of about 95 retatrutide exposure reports per month in the first four months of 2026. That's a 265% jump from the last four months of 2025, according to America's Poison Centers data cited in a CBS News investigation.

Those are exposure reports. They do not prove what was in each vial or that retatrutide caused every symptom. But they do show how quickly the underground market grew.

That same investigation found more than 120 websites and more than 50 clinics selling or promoting it.

A separate Public Citizen analysis found the FDA had sent 14 warning letters to retatrutide vendors since 2024 — and that as of May 2026, 11 of those companies were still advertising retatrutide or other unapproved peptides and 8 were still selling retatrutide itself.

One quick note on "GLP-3"

You'll see retatrutide called a "GLP-3." Lilly says that label is scientifically inaccurate. There's no such thing as a GLP-3 receptor. Retatrutide is a triple agonist — it activates three different receptors: GIP, GLP-1, and glucagon. We use the term on this page because that's what people search, not because it's correct.

Can't get retatrutide — what should you use now?

Zepbound is the closest FDA-approved option by mechanism, because it activates GIP and GLP-1 — two of retatrutide's three targets. Wegovy pen and Wegovy HD are approved weekly semaglutide shots. Wegovy pill and Foundayo are approved daily pills. If exact retatrutide is non-negotiable, the only legitimate routes are a qualifying clinical trial or Lilly's narrow physician-requested expanded access program.

The receptor ladder

This is the simplest way to see how close each option really is:

Zepbound gets you two out of three. Nothing approved gets you the third.

Here's the honest part

Zepbound does NOT activate glucagon — retatrutide's third target. That's a real difference and we're not going to soften it. If that exact three-receptor mechanism is your only priority, then a clinical trial or expanded access is genuinely the better path for you, not another online purchase. Skip ahead to the two legitimate doors.

But because Zepbound is already approved, it comes with things a vial never had: a printed label, a real pharmacy that has to answer for what's in the box, a dose ladder built from trial data, and a doctor who can adjust it when you feel sick. It is available now.

We'd put it this way: a smaller number you can trust beats a bigger number you can't.

Where each number actually comes from

This matters more than most people realize, so we label it everywhere on this page:

A company topline announcement and an FDA-reviewed label are not the same grade of evidence. Retatrutide's headline number is the only one on this list that hasn't been through FDA review.

None of these came from a head-to-head study. Different people, different lengths, different math. We'll show you what happens when you do line them up properly further down.

What is the closest FDA-approved alternative to retatrutide?

Zepbound (tirzepatide) is the closest FDA-approved alternative by receptor overlap. Its approved label reports an average 20.9% body weight reduction at 72 weeks on the 15 mg dose. Self-pay prices through LillyDirect start at $299 per 28-day KwikPen for the 2.5 mg starting dose and reach $449 per 28-day KwikPen for higher doses when the refill condition is met.

The $299 trap almost every page repeats

You'll see "Zepbound from $299/month" everywhere. Here's what that leaves out.

The 2.5 mg dose is a starting dose. It is not an approved maintenance dose. Lilly says so directly — the approved maintenance doses for weight are 5 mg, 10 mg and 15 mg.

So $299 is what you pay for roughly your first month. It is not your ongoing price.

Here's the real ladder:

One more thing nobody tells you: one "month" of Zepbound is 28 days, not a calendar month. We'll show you what that costs over a year in a minute. It's more than you think. The current Journey Program terms also expire December 31, 2026 and allow up to 11 KwikPen fills per calendar year, so no 12-month estimate is guaranteed.

Look at Zepbound first if you...

• Want the closest approved match to retatrutide's mechanism
• Are fine with a weekly injection
• Want the strongest average result on any approved label
• Need help getting insurance to cover it

Skip Zepbound if you...

• Need a pill — go to the pill comparison
• Can't sustain $399–$449 a month long term — go to the cost section
• Have a complicated medical history that needs a real conversation, not an online intake
• Want actual retatrutide and can reach a trial site — go to the access section

Does that sound like your situation? Check whether Zepbound fits you on Ro. Ro is a telehealth platform that prescribes FDA-approved GLP-1 medicines and handles insurance paperwork. Get started for $39 the first month, then as low as $74/month with the annual plan paid upfront. Medication is billed separately. Ro says you are charged the membership only if you are eligible for treatment. → Check your eligibility on Ro

Already have a doctor who'll write it? Then you don't need to pay anyone a membership. Go straight to LillyDirect and use the manufacturer-supported pharmacy channel. We'd rather tell you that than take a commission you didn't need to pay.

What if you don't want injections?

Wegovy pill and Foundayo are the two FDA-approved daily pill options compared here. Wegovy's 25 mg tablet reported a larger average result in its own label study (13.6% at 64 weeks) than Foundayo's 17.2 mg dose (11.1% at 72 weeks). Foundayo has the simpler routine because it can be taken any time of day, with or without food. Neither one is oral retatrutide.

Side by side

The routine test — answer this honestly

Will you actually take a pill first thing every morning, on an empty stomach, with a small sip of water, and then wait half an hour before your coffee?

If the answer is no, the "better number" may not be the better fit for you. These pills are meant to be taken once daily as prescribed. If the morning rule will make you miss doses, the easier routine is worth discussing with your prescriber.

That's not us being soft. That's the whole game with these drugs.

The deadline we mentioned up top

The Wegovy pill's $149 price for the 4 mg dose ends August 31, 2026. After that, the 4 mg dose is $199.

Here is the part that needs to be said correctly: this is normally a one-fill difference during the labeled dose climb, not a $50 increase every month. The 1.5 mg starting dose stays $149, and the 9 mg and 25 mg doses are $299 under the current price guide.

If you were going to start anyway, waiting past the deadline can cost you $50 on the 4 mg fill. It is not a $600-a-year penalty. Check the live manufacturer terms before you pay, because temporary offers can move.

→ See which pill fits your routine and budget — the finder compares both against your answers in about 60 seconds.

Are you really giving up that much by switching?

Retatrutide's headline 28.3% and Zepbound's 20.9% were not measured the same way, so the raw 7.4-point gap is not an apples-to-apples treatment difference. When we put both sets of published numbers on the treatment-regimen estimand and subtract each placebo result, the arithmetic gap is roughly 3.3 percentage points. That is our cross-trial calculation, not a head-to-head result or a prediction of the true difference.

This is the question underneath every other question on this page. Am I settling?

Four ways to compare the same two drugs

This is not a head-to-head study. It's our calculation using separate published figures from separate trials with different participants. It cannot predict what either drug would do for you specifically.

What that means in pounds

On a 250-pound person, at the separate 80-week and 72-week trial endpoints, a 3.3-point difference works out to about 8 pounds.

Eight pounds is not nothing. We're not going to insult you by pretending it is. But it's a very different decision than the one the headlines set up — which sounds like choosing between 70 pounds and 52.

And here's the part that should settle it: those trial numbers came from people on a supervised dose ladder with a clinician watching, adjusting, and slowing things down when they got sick. A vial in your fridge has no ladder and nobody watching.

The comparison that would actually answer this

A direct retatrutide-versus-tirzepatide trial exists. It's called TRIUMPH-5. The registry lists study activity through December 2026, but a study completion date is not a results date. No head-to-head results were posted as of August 21, 2026.

Until results are posted, anyone telling you exactly how much better retatrutide is — including us — is doing arithmetic across separate studies. We're just showing you our arithmetic.

What does a legal option actually cost for a full year?

Medication and care are two separate bills, and most price comparisons online only show one of them. At prices verified August 21, 2026, the 12-month medication run rates below range from about $3,288 to $5,637. They are not guaranteed bills because temporary offers can end or change. A telehealth platform adds about $708 to $1,678 in year one; using your own prescriber avoids the platform fee, but visits, labs and copays may still cost money.

The formula nobody prints

Your real cost = medicine + care fee + labs and visits − what insurance actually pays

The ad shows you one of those four. Sometimes none of them.

Year one, medication only

Our assumptions, printed so you can check them: self-pay, no GLP-1 coverage, starting from zero, following the labeled dose climb at the earliest allowed intervals, and keeping every refill condition. These are current-price run rates, not promises that an offer will last 12 months.

Math you can audit: Wegovy pill is $149 + $149 + 10 × $299. Foundayo with every top-dose refill on time is $149 + $199 + 10 × $299; each missed 45-day top-dose refill adds $50. Wegovy pen is 2 × $199 + 11 × $349. Zepbound is $299 + $399 + 11 × $449.

The 13th fill nobody counts

Look at that last column again.

A weekly injection is a 28-day supply. A year is 365 days. 365 ÷ 28 = 13.04.

For a simple 12-month cash model, weekly injections need 13 four-week fills, not 12. Thirteen 28-day fills cover 364 days.

The pill model uses 12 30-day bottles, which cover 360 days. Exact refill timing can pull a 13th pill bottle just inside or just outside a 365-day window, so treat every annual total here as a budget model, not a pharmacy quote.

Almost every injection estimate you'll read online multiplies by 12 and calls it done. On Zepbound at $449, that missing 13th four-week fill is $449 of real money that nobody warned you about.

Now add the care fee

So the Wegovy pill run rate with your own prescriber is about $3,288 plus any visit or lab costs under the August 31 offer. The Zepbound run rate through a monthly Ro membership is about $7,315 if the current medication offer continues and every high-dose refill stays inside 45 days.

That's about a $4,027 spread before doctor, lab or insurance costs — and it has nothing to do with which drug works better.

The cheapest legal paths, honestly

1. Wegovy pill or Foundayo at $149 to start, with a prescriber you already have. The higher-dose cost is different, so compare the full ladder above.
2. Medicare GLP-1 Bridge: $50/month. If you have Medicare Part D and qualify, this is the lowest verified program price on this page. It currently runs through December 31, 2027.
3. Commercial insurance that covers the drug: as low as $25/month under the Wegovy savings terms shown here. Government beneficiaries are excluded from that offer.
4. A plan appeal, exception or product-specific help program if you qualify. Do not assume a medicine is included until the current program names it.

None of those are affiliate links. They're just the truth about what's cheapest.

Will insurance or Medicare cover any of this?

Commercial coverage depends on your specific plan, your diagnosis, and its prior authorization rules. Ro's free coverage checker currently checks Ozempic, Wegovy injection and Zepbound injection — not Foundayo, the Wegovy pill or Zepbound vials. Eligible Medicare Part D beneficiaries may get Foundayo tablets, Wegovy injections or tablets, or Zepbound KwikPen for a $50 monthly copay through the Medicare GLP-1 Bridge, which currently runs through December 31, 2027. The Bridge does not cover Zepbound vials or single-dose autoinjector pens; only the multi-dose KwikPen is covered.

What "prior authorization" means

Your insurance company makes your doctor fill out paperwork proving you meet their rules before they'll pay. It's the step that eats weeks and phone calls. It's also the single biggest reason people give up.

What Ro's free checker actually checks

We're printing this because we've seen it described as a universal GLP-1 checker. It isn't. Straight from Ro's own page:

If your door is the Wegovy pill or Foundayo, the checker won't help you — use the manufacturer-supported pharmacy channel instead. If it's Zepbound or Wegovy pens, it's genuinely useful and it's free.

Medicare GLP-1 Bridge

If you're on Medicare Part D, this is worth ten minutes of your time. Eligible people pay $50 per month for Foundayo tablets, Wegovy injections or tablets, or Zepbound KwikPen. It went nationwide on July 1, 2026 and currently runs through December 31, 2027.

The catches, stated plainly: you need an eligible Part D plan, you need to meet the clinical criteria, and prior authorization applies. The Bridge does not cover Zepbound vials or single-dose autoinjector pens; only the multi-dose KwikPen is covered. What you spend through the Bridge does not count toward your Part D deductible or annual out-of-pocket limit.

Not sure which BMI rule you meet? Use the BMI eligibility calculator.

The single fastest thing you can do right now: find out whether your plan covers any GLP-1 at all. That one answer changes your cost more than every other decision on this page combined.

Ro runs that check free and, if you're covered, their team handles the prior authorization paperwork for you. → Check your coverage free on Ro

Remember the scope above — the checker covers Ozempic, Wegovy and Zepbound pens.

The deadlines working against you right now

Every legal option carries a timing rule, and someone restarting after a gap is especially likely to trip one. Five timing rules matter here: the Wegovy pill's 4 mg offer ends August 31, 2026; the Wegovy pen's two-fill introductory price runs through December 31, 2026; Zepbound's $449 high-dose price requires a refill within 45 days, and its current card terms end December 31, 2026 with an 11-fill calendar-year cap; Foundayo's $299 top-dose offer has the same 45-day rule and its savings card ends December 31, 2026; and the Medicare GLP-1 Bridge currently runs through December 31, 2027.

We built this table because we couldn't find it anywhere else. Every one of these came from a manufacturer's own page.

The 45-day trap — this one costs the most

If you're restarting, you may pause. You may travel. A prescription may get stuck at the pharmacy. That's exactly when this rule bites.

Here's the real damage from the current Lilly terms:

An older Lilly release listed $599, $699, $849 and $1,049 for certain vial doses. Those are not the current KwikPen regular prices. The current page verified August 21, 2026 lists $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg.

Set a calendar reminder for day 30. That's it. That's the whole fix, and it's worth up to $250 under the current terms.

What does switching from retatrutide actually involve?

There is no FDA-labeled or trial-validated dose conversion from retatrutide to an approved drug. Expect the new medicine to follow its own labeled start and dose climb unless a prescriber has a product-specific, label-supported reason to do something different. Zepbound, Wegovy and Foundayo all say they should not be used with another GLP-1 receptor agonist. Your prescriber decides the timing of any switch.

You'll start at the bottom. That's normal, not a punishment.

A prescriber should not guess at a dose that "matches" what a vial claimed to contain. Not because they don't believe you — because there is no validated retatrutide conversion in an FDA label or completed switching trial.

Each approved option has its own labeled start and dose climb. That climb is designed to reduce stomach side effects. It's also, we'd argue, the thing a vial could never give you.

Can you overlap them? The labels already answered

This is the question everyone asks and almost nobody addresses.

• Zepbound's label says it shouldn't be used with other tirzepatide products or any GLP-1 receptor agonist medicines.
• Wegovy's label says it shouldn't be used with other semaglutide products or other GLP-1 receptor agonist medicines.
• Foundayo's label says it shouldn't be used with other orforglipron products or any other GLP-1 receptor agonist medicines.

Retatrutide hits three receptors, and GLP-1 is one of them. So the label of the drug you're switching to already tells you these don't get stacked.

We're not going to give you a wait time or a washout schedule. That's a prescriber's call based on your specific situation, and anyone publishing a number for it online is guessing with your body. Ask. Don't self-manage it.

What to expect when the old drug wears off

Your appetite may rise as the old product wears off. That can happen. It is not failure, and it's not proof the drug "broke" you.

It's also the reason not to drift. The window between stopping one thing and starting another is where people lose ground — and the deadlines above mean drifting has a dollar cost too.

Do you have to tell your doctor what you were taking?

Yes. And we know that's the actual reason some of you have been putting this off.

Here's a script. Use it word for word if you want:

"I was using a product I bought online that was labeled retatrutide. I've stopped. I'd like to start something prescribed and supervised."

That's it. No explanation, no apology.

Why it matters medically: they need the full story to plan labs, timing, a labeled starting dose, and anything that needs attention. The poison-center reports above show that this is not a one-person problem.

You do not need to defend the purchase. You need to tell the truth so they can treat you safely.

Six questions to bring to your appointment

1. Which approved option fits my health history best?
2. Does my insurance cover any of them?
3. What starting dose makes sense given what I was taking?
4. How long before we adjust it?
5. What side effects mean I should call you?
6. Can you send the prescription to a manufacturer pharmacy to keep the cost down?

What if you plateaued on your highest dose?

A slowing scale is not automatically proof that a medication has stopped working. Before switching, a clinician should review how long you've been at your current dose, whether hunger has actually returned, your weight trend over months rather than weeks, and whether another medicine or condition is affecting your weight. Zepbound's approved maintenance doses are 5 mg, 10 mg and 15 mg, so "the highest dose" means something specific worth confirming.

A lot of people looking for retatrutide aren't blocked. They're stuck. They maxed out on Zepbound, the scale stopped, and retatrutide started looking like the next level.

We want to slow that down for a second.

Plateau is not the same as stopped working

• Weight loss almost always slows. That's the expected shape of it.
• Holding a large loss steady is the drug working. Maintenance is a real outcome, not a failure.
• A few flat weeks isn't a plateau. A few flat months might be.
• Appetite returning and the scale being flat are two different problems with two different answers.

We're not going to diagnose you with "GLP-1 resistance." That's not a thing you can determine from a webpage.

Questions worth asking before you switch anything

• How long have I actually been at this dose?
• Has my weight been flat long enough to call it a plateau?
• Has my hunger genuinely come back, or is the scale just slow?
• Could another medication or condition be involved?
• Am I still holding a loss I fought hard for?
• Would joining a trial require me to stop this first?

One trial rule that catches people here

If you're thinking "I'll just get into a retatrutide trial instead" — read this first.

The TRIUMPH-5 protocol excludes recent weight-loss drug use within 90 days of screening. Other studies can use different windows. Stopping a current medicine to chase one trial could mean up to three months without it — and still no guarantee you qualify.

Do not stop a working medication to chase a trial slot. Talk to your clinician first.

No sales pitch in this section. If you're plateaued, what you need is a treatment review, not a checkout page.

What if you don't have a doctor, or yours said no?

Two routes work here. Telehealth platforms can prescribe FDA-approved GLP-1 medicines and handle insurance paperwork for a monthly or annual fee. Or, if any prescriber will write the prescription, you can use the manufacturer-supported pharmacy channel — LillyDirect for Zepbound and Foundayo, NovoCare Pharmacy for Wegovy and Ozempic — and avoid a telehealth membership. The medication price may match the manufacturer cash offer, but taxes, fees and program eligibility still apply.

Straight to the manufacturer is the cheapest route

LillyDirect and NovoCare Pharmacy are manufacturer-supported pharmacy channels, not a way around a prescription.

NovoCare publishes free shipping, FSA/HSA card acceptance and 90-day supply options. LillyDirect publishes home-delivery access for its products. Terms differ by medicine and can change.

You still need a valid prescription. That's the only catch.

When your doctor can't find the pharmacy in their system

This is a small, stupid, real problem that stops people cold: a willing doctor who types "NovoCare" into their prescribing software and gets nothing.

Here's everything they need, from Novo's own instructions:

NovoCare® Pharmacy 2400 Sand Lake Rd, Ste. 200B, Orlando, FL 32809 Phone: 1-833-949-5527 Fax: 1-833-947-0246 NPI: 1710671854 NCPDP: 5758074

Print that. Hand it over. Most systems let a prescriber add a pharmacy manually with those two ID numbers.

Already have a prescription sitting at another pharmacy? Ask that pharmacy to call 1-833-949-5527 and transfer it. You don't have to start over.

One more useful detail: some manufacturer self-pay offers can be used outside insurance, even by someone enrolled in a government plan, but the exact product terms control and the purchase cannot be submitted to the plan for reimbursement.

Honest downside: money paid outside the plan generally doesn't count toward its deductible or out-of-pocket limit. If you're close to hitting either one, run the numbers through your plan first.

What a telehealth membership actually buys you

Not the drug. Ro may route eligible prescriptions to the same manufacturer cash-pay channels you could use with another prescriber; the manufacturer sets those medication prices.

What you're paying for is the system around it: the insurance concierge that fights the prior authorization, the prescriber who reviews your labs and adjusts your dose, and the check-ins.

If you already have a doctor who'll write the prescription, you don't need this. We just told you that before recommending anyone, because everything we say after an honest negative should be worth more.

What real patients say about the medication

We won't use underground retatrutide testimonials as social proof. A post cannot prove what was in the vial, how it was made, or what dose the person actually used.

What we can show you is the review record for the drug we're actually pointing you toward.

On Drugs.com, Zepbound holds an 8.6 out of 10 from 739 reviews. 79% of reviewers report a positive experience; 3% report a negative one. Filtered to weight loss specifically, it is 8.7 out of 10 from 652 reviews as of August 21, 2026.

One verified reviewer put the upside simply:

"Thank you Zepbound for showing me what being full was." — Drugs.com reviewer

The same page also includes people reporting nausea, vomiting, fatigue, constipation and other side effects strong enough to make them stop. That negative evidence stays here on purpose. It is also a good argument for having a real prescriber instead of a vial.

These are voluntary, self-selected reviews. They are individual experiences, not typical results, and not evidence of safety or effectiveness. Your results will be your own.

If you don't have a prescriber — or yours won't write it — that's the exact gap Ro fills. Free eligibility check first. $39 for your first month, then as low as $74/month with the annual plan paid upfront. Medication billed separately at manufacturer prices. → See if you qualify on Ro

Would you rather pick your own clinician? Sesame lists individual providers and their prices upfront, and shows current program pricing for options including Wegovy, Zepbound, Foundayo and Ozempic. → Compare providers on Sesame Care

Is there any legal way to get actual retatrutide?

Yes — two narrow routes. A qualifying clinical trial, or Eli Lilly's expanded access program, which the company confirmed publicly on August 3, 2026. The expanded access record (NCT07629401) has been listed as "Available" since June 5, 2026. Requests must be initiated by a treating physician, not by patients.

Most pages you'll read still say clinical trials are the only legal route. That's been out of date since June 5, 2026. If a page tells you trials are your only option, it hasn't been updated since early June.

Door 1: Expanded access

"Expanded access" (sometimes called compassionate use) is a legal pathway for getting an unapproved drug outside a trial when someone is seriously ill and has no other options.

The listed criteria — all of them must be met:

1. Age 18 or older
2. BMI of at least 35 and obesity that hasn't responded despite taking and tolerating the highest available dose of an approved weight-management treatment
3. Two or more serious or life-threatening obesity-related complications, currently being treated
4. Unable to join a trial — either you don't meet the criteria, or there's no reasonably reachable site near you
5. All standard options discussed, including bariatric surgery

Criterion 4 is more open than most coverage suggests. "No trial site I can realistically get to" counts as a reason.

Criterion 2 is the one that stops most people. It means you have to have already tried an approved drug at its top dose. Which, for most readers of this page, is the actual answer to what do I use now — start one.

How it works: your treating doctor contacts Lilly through the Lilly Answers Center at 1-800-545-5979. The request cannot be started by the patient. Lilly says it aims to respond to physician requests within five business days. Meeting the criteria does not guarantee access — Lilly review, supply, geography, FDA authorization and local oversight can still apply.

Door 2: A clinical trial

Trials are enrolling in some states. Worth checking if you're motivated.

Before you go down that road, know what you're agreeing to: screening visits, possible placebo depending on the study, travel and a fixed schedule. TRIUMPH-5 uses a 90-day recent-medication exclusion, but other trial rules can differ. Ask the site before stopping anything.

What to ask a trial site before you commit

• Is this study actually recruiting at this location right now?
• Is there a placebo group, and what are my odds?
• Can I stay on my current medication?
• Is there a washout period, and how long?
• How many visits, and who pays for travel?
• What happens when the study ends?
• Who handles it if I have side effects?

→ Search recruiting studies at ClinicalTrials.gov or Lilly Trial Guide. No affiliate link here — this is just where the information lives.

What if you already have retatrutide at home?

This section is information only. U.S. poison centers logged roughly 95 retatrutide exposure reports per month in early 2026, a 265% increase over late 2025. The FDA warns that unapproved online GLP-1 products may contain the wrong amount of active ingredient, no active ingredient, or harmful ingredients. If you feel unwell, contact Poison Control at 1-800-222-1222.

No product or purchase links in this section. No recommendations. Nothing to buy.

What's actually been found in these products: the FDA has warned about products falsely labeled "for research purposes" or "not for human consumption" that were sold to people with dosing instructions anyway. It describes them as being of unknown quality and potentially harmful.

What we won't do here: we're not going to tell you how to taper, how to store it, how to test it, or how to use it more safely. There's no version of that advice that doesn't amount to helping you inject something nobody can identify.

If you feel unwell — especially with severe or lasting stomach pain, repeated vomiting, yellow skin or eyes, dark urine, confusion, fainting, or trouble keeping fluids down — call a clinician or Poison Control now.

• Poison Control: 1-800-222-1222 (free, 24/7)
• FDA MedWatch: report online or call 1-888-INFO-FDA and press 2
• Call 911 for collapse, seizure, trouble breathing, or someone you can't wake up

Calling Poison Control is about getting medical help, not getting judged.

Should you just wait for retatrutide to be approved?

Lilly plans to submit its U.S. application in the first quarter of 2027. After a submission, the FDA still has to review it, and a company still has to launch it. Even in a fast scenario, that points to an approval decision no earlier than late 2027 and more likely 2028, plus launch time. There is no confirmed approval date, price, or coverage.

The honest math on waiting

Lilly previously discussed a late-2026 filing window. Its current public plan is the first quarter of 2027. The company has not announced a guaranteed filing day, FDA review class or approval day.

After a filing and acceptance: FDA's review goal is generally about 10 months for standard review or 6 months for priority review. Then Lilly has to launch the product and payers have to decide whether to cover it.

Add it up honestly: late 2027 is a fast-path possibility, not a promise. Early 2028 is the cleaner standard-review estimate.

What waiting actually costs you

It isn't just weight. It's four dated things:

• The Wegovy pill's 4 mg fill rises from $149 to $199 after August 31, 2026; the $149 starting dose does not disappear
• The $199 Wegovy pen intro for two fills ends December 31, 2026 under current terms
• The Foundayo savings card expires December 31, 2026, and its $299 top-dose price also needs an on-time refill
• The current $50 Medicare Bridge ends December 31, 2027 unless extended

Waiting might genuinely make sense if...

• You're doing well on a treatment right now
• Your clinician agrees there's no urgent reason to change
• You're not going to buy an unregulated substitute while you wait

That last one is the whole thing. Waiting is a reasonable choice. Waiting while injecting something from the underground market Lilly and FDA are targeting is not waiting — it's the risk without the reward.

If you've decided to start something real, the first step costs nothing: find out what your insurance will actually cover. → Start your free coverage check on Ro

How we built this page and what we verified

We checked every price on this page against the manufacturer's own pages on the date shown. Regulatory statements come from the FDA and Eli Lilly directly, not from news summaries. Where sources disagreed, we published the manufacturer's number and said so.

What we actually verified

A correction we made to our own page

An earlier draft used Lilly's December 2025 release and listed Zepbound missed-window prices of $599, $699, $849 and $1,049. Lilly's current KwikPen terms now list $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. We corrected the table to the current page rather than keeping an older press release.

We're leaving this note here rather than quietly editing it, because you should know when a page you're trusting got something wrong.

What we couldn't verify for everyone

• Whether your specific insurance plan will approve you
• Medicaid coverage in every state — it varies too much to generalize
• Whether any of these temporary prices get extended
• Whether a specific trial is still enrolling today
• Whether an expanded access request will be granted
• Retatrutide's eventual approval date, price, or label

Who made this and why

By Kaden, founder of Weight Loss Provider Guide, an independent comparison resource for GLP-1 telehealth providers. No clinician reviewed this page. We're not going to put a doctor's name on it to look more official.

Why it exists: when someone finds out they can't get retatrutide, most of the internet either sells them a vial or tells them to wait. We built this to lay out every legal option, what each one really costs, and the two legitimate ways to request the actual drug — in one place, with the sources printed.

How we make money: some links here are affiliate links. It doesn't change what we verify, and you'll notice we point you to the free and cheaper routes — LillyDirect, NovoCare, ClinicalTrials.gov, Medicare Bridge — every time one of them is the better answer.

Common questions

Why can't I get retatrutide anymore? It isn't approved in any country. The FDA says it can't be used in compounding under federal law. On August 12, 2026, Lilly sued six sellers and asked online platforms, payment companies and shipping carriers to stop supporting illegal sales. That pressure can make underground sources disappear, although we can't know why any one seller shut down.

Is it illegal to buy retatrutide? FDA says selling unapproved retatrutide for human use is illegal. A "research use only" label does not turn a consumer weight-loss sale into an approved medicine. State law can add other rules, so this page does not give you personal legal advice.

Can my doctor just prescribe retatrutide? No. There's no approved product to prescribe. Your doctor can request it through Lilly's expanded access program if you meet all five listed criteria, but that request comes from them, not from you.

What's the closest FDA-approved thing to retatrutide? Zepbound. It activates GIP and GLP-1 — two of retatrutide's three receptors. It does not activate glucagon, so it isn't the same medicine.

What's the cheapest legal option? For self-pay, the Wegovy pill and Foundayo both start at $149 a month. If you have Medicare Part D and qualify for the GLP-1 Bridge, $50 a month is cheaper. With commercial insurance that covers GLP-1s, savings cards can bring it to $25.

Can I take retatrutide and Zepbound at the same time? Zepbound, Wegovy and Foundayo labels say not to use them with another GLP-1 receptor agonist medicine. Retatrutide activates GLP-1. Ask your prescriber about timing — don't manage this yourself.

Will I gain the weight back if I switch? Appetite may rise after a GLP-1 medicine is stopped, but a switch does not guarantee regain. The safe way to keep the gap as short as your case allows is to plan the timing with a prescriber instead of guessing.

Do I have to start over at the lowest dose? There is no validated retatrutide conversion. Expect the new drug to follow its own labeled start and dose climb unless your prescriber has a product-specific, label-supported plan.

When will retatrutide be approved? Unknown. Lilly plans to file in the first quarter of 2027. A priority-review path could put a decision in late 2027; a standard-review path points more cleanly to 2028. Neither is promised.

Do I have to tell my doctor what I was taking? Yes. They need it to plan labs, timing and a safe labeled start. A simple version works: you used a product bought online labeled retatrutide, you've stopped, and you'd like something prescribed and supervised.

Can I use HSA or FSA money? NovoCare Pharmacy accepts FSA and HSA cards. Whether your plan will reimburse a specific purchase depends on its rules, so check with your plan administrator.

What if I already have a vial at home? Don't use it before talking to a clinician or pharmacist. Bring the packaging and any receipts. If you feel unwell, call Poison Control at 1-800-222-1222.

Is "GLP-3" a real thing? No. There's no GLP-3 receptor. Lilly says the term is scientifically inaccurate. Retatrutide is a triple agonist targeting GIP, GLP-1 and glucagon.

What if I can't take a GLP-1 medicine at all? Talk to a clinician about other evidence-based options, including other medications and surgical routes. Don't substitute a supplement marketed as a "natural GLP-1" — those aren't the same category of thing.

Where this leaves you

You don't have to choose between waiting forever and trusting a mystery vial. That was never the actual choice.

Zepbound is the closest approved option by mechanism, at $299 to start. The Wegovy pill and Foundayo start at $149. Actual retatrutide has exactly two legitimate doors — a trial, or a physician-requested expanded access application — and neither one runs through an online checkout.

The right path depends on your health, your coverage, your budget, your tolerance for needles, and what you've already tried.

One last thing: the Wegovy pill's 4 mg fill has an August 31, 2026 price deadline. If you were going to start anyway, meeting it can save $50 on that fill. The $149 starting dose does not disappear after the deadline.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz — you'll get a practical route based on your budget, coverage, pill-or-shot preference and whether you already have a prescriber. No email required to see your result.

This page is for general information and isn't medical advice. It doesn't replace a conversation with a qualified clinician who knows your history. Prices and program terms change — open the source links before you pay for anything.